很高興和大家分享，臨床腫瘤科專科張文龍醫生早前於 Best of ASCO 2025, Hong Kong 擔任肺癌及泌尿科腫瘤環節（Lung and Urological Cancers Session）的主持人，帶領國際專家和醫療專業人士深入探討肺癌治療的最新研究成果與未來發展方向。

Best of ASCO 2025, HONG KONG 是由美國臨床腫瘤學會（ASCO）與香港國際腫瘤臨床研究學會（HKIORS）聯合舉辦的年度學術盛事，已於7月5日圓滿落幕。活動將 2025 年全球最新、最具突破性的腫瘤學研究成果帶到香港，幫助本地及亞太地區的醫療專業人士掌握癌症治療的新趨勢與臨床進展。

在張醫生主持的肺癌專場中，邀請了國際知名學者 Prof. Shun Lu 及 Prof. Patrick Forde。他們分享了關於非小細胞肺癌治療的最新研究成果，與會者圍繞肺癌治療領域的最新臨床進展展開了深入討論。這些突破性研究不僅為提升患者治療效果帶來了新希望，也對臨床實踐產生了深遠影響。

It is with great pleasure that I share Dr. Teo Man Lung recently presided over the Lung and Urological Cancers Session at Best of ASCO 2025, Hong Kong. He led a panel of international experts and medical professionals in a thorough discussion on the latest research findings and future directions in lung cancer treatment.

Best of ASCO 2025, Hong Kong, a joint annual academic event formally licensed by the American Society of Clinical Oncology (ASCO), in collaboration with the Hong Kong International Oncology Clinical Research Society (HKIORS), concluded successfully on July 5th. The event brought the latest and most groundbreaking oncological research of 2025 to Hong Kong, aiding local and Asia-Pacific medical professionals in keeping abreast of new trends and clinical advancements in cancer treatment.

The lung cancer segment featured renowned scholars, Prof. Shun Lu and Prof. Patrick Forde, who shared their latest research on the treatment of non-small cell lung cancer. The discussions were deep and focused on recent clinical advancements in the field of lung cancer treatment. These groundbreaking studies not only bring new hope for improving patient treatment outcomes but also have a profound impact on clinical practices.